2 – Epidemiology
Myeloma represents 2% of all malignant diseases, with an incidence of 9.3/100,000 per year accounting for approximately 5500 new cases each year in the UK (representing roughly 2900 deaths per year) [4,6]. The median age at diagnosis is 69 years, but 24.1% of patients are diagnosed after 75, and 9.2% after 85 . This is likely to increase in the years to come especially in Europe where it is foreseen that the percentage of Europeans aged over 65 will increase from 18% of the population in 2013 to 28% of the population in 2060 . Population-based US studies suggest that the 5-year relative survival is 30.3% for patients with multiple myeloma (MM) aged over 75 years, which is under half of that of patients aged under 65 years (62.4%), suggesting that progress still needs to be made for these patients . The UK population data are largely consistent with this, with a five-year net survival of 25% for those aged 80–99 years at diagnosis and 44% for those aged 70–79 years at diagnosis [4,6].
All topics within this chapter
3. Biological and clinical features
4. Defining aims
5. What to aim for?
6. Disease-specific treatment options
7. Tailoring the treatment to the patient
8. Supportive care
9. Conclusion and perspectives
Chapter 1 – Pathophysiology
Chapter 2 – Diagnosis and staging
Chapter 3 – Treatment of transplant-eligible patients
Chapter 4 – Treatment of elderly patients with myeloma
Chapter 5 – Treatment of relapsed multiple myeloma
Chapter 6 – Bone disease